MEI Pharma to price $45 million public offering of its common shares

Bookrunner BofA Merrill Lynch and co-managers Cowen and Stifel assist

By Devika Patel

Knoxville, Tenn., Dec. 10 – MEI Pharma, Inc. will price a $45 million public offering of common stock with a $6.75 million greenshoe, according to a preliminary prospectus supplement filed Wednesday with the Securities and Exchange Commission.

BofA Merrill Lynch is the bookrunner. Cowen and Co. LLC and Stifel Nicolaus & Co. Inc. are the co-managers.

Proceeds will be used for the clinical development programs for Pracinostat, ME-344 and PWT143 and other general corporate purposes.

The oncology company is based in San Diego.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.